Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Novel PET-CT method superior to conventional imaging in detecting high-risk localized prostate cancer

Pank Jit Sin
31 Mar 2020
A novel imaging technique using prostate-specific membrane antigen positron emission tomography – computed tomography (PSMA PET-CT) is a suitable replacement for conventional imaging, a study reveals. [Lancet doi.org/10.1016/S0140-6736(20)30314-7]


The multicenter, two-arm, randomized study looked at men with biopsy-proven prostate cancer and high-risk features at 10 hospitals in Australia. [Australian New Zealand Clinical Trials Registry ANZCTR12617000005358] Patients were randomized to undergo either conventional CT and bone scanning or gallium-68 PSMA-11 PET-CT. First-line imaging was performed within 21 days of randomization. Patients were crossed over unless three or more distant metastases were identified. The study’s primary outcome looked at the accuracy of first-line imaging for identifying either pelvic nodal or distant-metastatic diseases, which is defined by the receiver-operating curve using a predefined reference standard, and includes histopathology, imaging and biochemistry at 6-month follow-up.

The study found that PSMA PET-CT had a 27 percent (95 percent CI 23–31) greater accuracy compared to conventional imaging (92 percent [88–95] vs 65 percent [60–69]; p<0.0001). Additionally, conventional imaging was less sensitive and specific compared to PSMA PET-CT. PSMA PET-CT also proved to be superior to conventional imaging for patients with pelvic nodal metastases and patients with distant metastases.

The study also noted that radiation exposure was higher in conventional imaging compared with PSMA PET-CT (19.2 mSv vs 8.4 mSv; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.